7Vergote IB, Declodet J. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer [ J ]. Semin Oncol,2001,27( 1 ) :31. 被引量：1
3Burger RA, Sill MW, Monk B J, et al. Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study[ J ]. J Clin Oncol, 2007,25: 5165-5171. 被引量：1
4Markman M, Liu PY, Wilczynski S, et al. Phase Ⅲ randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial[J]. J Clin Oncol, 2003, 21 : 2460-2465. 被引量：1
5Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup Trial of the AGOOVAR, the NCIC CTG, and the EORTC GCG[J]. J Clin Oncol, 2006,6:913-918. 被引量：1
6Sorbe B. Swedish-Norwegian Ovarian Cancer Study Group: consolidation treatment of advanced (FIGO) stage ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy,chmotherapy, and no further treatment [J ]. Int J Gynecol Cancer, 2003,13 ( 3 ) : 278 -286. 被引量：1
7Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? [ J ]. Gynecol Oncol, 1993,51:97-103. 被引量：1
8[1]Thigpen TJ, Vance RB, Khansur T. Second line chemotherapy forrecurrent carcinoma of the ovary. Cancer, 1993,71(Supp 14 ):1559-1564. 被引量：1
9[3]Tentes AA,Tripsiannis G,Markakidis SK,et al. Peritoneal cancer index:a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol,2003,29:69-73. 被引量：1
10[5]Hoskins WJ,Mc Guire WP,Brady MF,et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol,1994,170:170-174. 被引量：1
1Therasse P, Arbuck SG, Eisenhaner EA, et al. New guidelines to evalu- ate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the U- nited States, National Cancer Institute of Canada [ J ]. J Natl Cancer Inst, 2000,92(3) :205 -216. 被引量：1
2Goto T, Takano M, Ohishi R, et al. Single nedaplatin treatment as sal- vage chemotherapy for platinum/taxane - resistant/refractory epithelial ovarian, tubal and peritoneal cancers [ J ]. J Obstet Gynaeeol Res, 2010,36(4) :764 -768. 被引量：1
